A novel antithrombin domain dictates the journey's end of a proteinase.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

1. Identification and characterization of two SERPINC1 mutations causing congenital antithrombin deficiency.Thrombosis journal · 2023
   Article

Corrections and comments

• Comment on
  Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.2017

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

Indexed as